Reaction
Pulmonary Veno-Occlusive Disease reporting signals
As of the last recalculation, Pulmonary Veno-Occlusive Disease appears in 687 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is EPOPROSTENOL (PRR 141.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Epoprostenol | 56 | 141.0 | 141.6 |
| Selexipag | 84 | 112.1 | 112.5 |
| Thiotepa | 30 | 99.5 | 99.8 |
| Sildenafil Powder, | 73 | 69.4 | 69.6 |
| Busulfan | 34 | 68.8 | 69.0 |
| Macitentan | 125 | 66.6 | 66.8 |
| Sildenafil | 105 | 64.6 | 64.8 |
| Bosentan | 80 | 54.3 | 54.4 |
| Tadalafil | 114 | 41.2 | 41.2 |
| Sildenafil Citrate | 138 | 40.8 | 40.9 |
| 0Xygen | 56 | 37.4 | 37.5 |
| Oxygen | 56 | 37.4 | 37.5 |
| Riociguat | 37 | 36.3 | 36.3 |
| Melphalan | 24 | 33.1 | 33.1 |
| Melphalan Hydrochloride | 26 | 32.6 | 32.6 |
| Treprostinil | 113 | 32.5 | 32.5 |
| Mesna Injection | 8 | 29.7 | 29.7 |
| Mesna | 8 | 29.1 | 29.1 |
| Tolvaptan | 13 | 27.6 | 27.6 |
| Ambrisentan | 92 | 25.6 | 25.6 |
| Fludarabine Phosphate | 28 | 22.4 | 22.5 |
| Etoposide | 36 | 15.6 | 15.6 |
| Canakinumab | 5 | 14.1 | 14.1 |
| Ifosfamide | 9 | 12.8 | 12.9 |